Gene test may spare some breast cancer patients chemo
NCT ID NCT03961880
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This study looked at 270 women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Researchers used the OncotypeDX test to see how its recurrence score influenced whether doctors recommended chemotherapy. They also checked if the score was linked to cancer cells found in the bone marrow. The goal was to better understand how this test can guide treatment decisions in routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department for Women's Health
Tübingen, Baden-Wurttemberg, 72086, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OncotypeDX recurrence score test
What this could lead to
If successful, this could help doctors better personalize chemotherapy decisions for early breast cancer patients, avoiding unnecessary treatment.
What could go wrong
This is an observational registry, not a treatment trial. It does not test a new drug or therapy, so it cannot directly improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.